[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 16 days · First seen · Last updated

Celltrion drug pipeline development

Overview

South Korean biotech firm Celltrion is advancing several drug development programs, specifically focusing on an obesity drug candidate, CT-G32, and a pipeline of antibody-drug conjugates (ADC) for cancer treatment.

Regarding the obesity drug CT-G32, the company expects to conclude toxicology studies in rodents and monkeys this year, with plans to submit an Investigational New Drug (IND) application by February and begin first-patient dosing in the second quarter of 2025.

In its cancer therapeutics pipeline, Celltrion’s ADC candidates—CT-P70, CT-P71, and CT-P73—have all received Fast Track designation from the U.S. Food and Drug Administration (FDA). These candidates target c-MET, Nectin-4, and tissue factor, respectively. CT-P73 is specifically noted for targeting recurrent and metastatic cervical cancer. The company is currently conducting Phase 1 trials for these candidates and expects to release top-line results sequentially starting in the first half of next year.

Entities

Celltrion · CT‑P70 · U.S. Food and Drug Administration (FDA) · CT‑G32 · U.S. Food and Drug Administration

Timeline

  1. 14 days ago

    [BUSINESS] 3 sources
    Celltrion ADC drug candidates receive FDA Fast Track designation

    Celltrion's three ADC cancer drug candidates, CT-P70, CT-P71, and CT-P73, have all received FDA Fast Track designation to accelerate their development and review processes.

  2. 29 days ago

    [BUSINESS] 2 sources
    Celltrion pushes obesity drug CT‑G32 and ADC cancer pipeline forward

    Celltrion will present preclinical data on obesity drug CT‑G32 in November and aims for first dosing in 2025, while its four ADC cancer candidates move through Phase 1 with early results expected next year.

Sources

biz.heraldcorp.com · kormedi.com · news.heraldcorp.com